Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in the Philippines has been steadily increasing over the past few years.
Customer preferences: Customers in the Philippines are increasingly seeking out Anti-Rheumatic Drugs that are both effective and affordable. With a growing aging population, the demand for these drugs is expected to continue to rise. Additionally, customers are looking for drugs that have minimal side effects and can be easily accessed.
Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in the Philippines is the increasing availability of generic drugs. This has made these drugs more affordable and accessible to a wider range of customers. Another trend is the increasing use of biologic drugs, which are more effective but also more expensive. However, with the increasing availability of health insurance and government support for those in need, more customers are able to access these drugs.
Local special circumstances: The Philippines has a large aging population, which is driving the demand for Anti-Rheumatic Drugs. Additionally, the country is prone to natural disasters such as typhoons and earthquakes, which can lead to an increase in cases of rheumatoid arthritis and other related conditions. The country also has a high prevalence of infectious diseases, which can lead to secondary rheumatic conditions.
Underlying macroeconomic factors: The Philippines is experiencing steady economic growth, which has led to an increase in healthcare spending. The government has also implemented policies to improve access to healthcare, including the implementation of a universal healthcare system. Additionally, the country has a growing pharmaceutical industry, which is driving innovation and competition in the Anti-Rheumatic Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)